| Document |
Document Title |
|
WO/2021/072339A1 |
Disclosed is a continuous process for the purification of steviol glycosides such as Rebaudioside D and/or Rebaudioside M extracted from the dried stevia leaves or extracted from a fermentation broth using continuous simulated moving bed...
|
|
WO/2021/071800A1 |
The present application is directed to pharmaceutical combinations comprising mithramycin and immunotherapy to target cancer initiating stem cells (CSCs). The present application also discloses methods of treating cancer comprising admin...
|
|
WO/2021/069773A1 |
The invention relates to a detection compound or probe that exhibits high diuretic activity and comprises a signalling unit (fluorophore) bearing negatively charged functional groups (anionic groups). The recognition unit, which consists...
|
|
WO/2021/064052A1 |
The present invention relates to the field of medicine, in particular of oncology. Especially, it provides new compounds useful in the treatment of various cancers, such as glioblastoma, colorectal or breast cancers. The present disclosu...
|
|
WO/2021/062882A1 |
A method for synthesizing rosavin, comprising the steps of: using trimethylsilyl trifluoromethanesulfonate to catalyze 2,3,4-tri-O-acetyl-L-arabinofuranoside trichloroacetimide ester and ethyl 2,3,4-tri-O-acetyl-beta-D-thioglucopyranosid...
|
|
WO/2021/063075A1 |
The present invention relates to the technical field of biomedicine, and disclosed are an albiziae cortex lignan compound and an application thereof. The compound prepared by the present invention can effectively treat FFAs-induced lipid...
|
|
WO/2021/056270A1 |
Senolytic prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to release the active parent ...
|
|
WO/2021/062273A1 |
Described herein are methods for evaluating polymer compositions comprising polymers modified with a small molecule compound (e.g., afibrotic compound), including methods for determining the concentration levels of said compounds.
|
|
WO/2021/061873A1 |
Provided herein are methods of treating polycystic kidney disease (PKD) associated with one or more nonsense mutations in a PKD2 gene in a subject using one or more aminoglycosides selected from NB122, NB124, NB84, NB127, NB118, NB128, N...
|
|
WO/2021/054474A1 |
In the present invention, a disaccharide unit for synthesizing a useful sugar chain for suppressing the development of dystroglycanopathy is obtained and used to reconstitute a post-phosphoryl sugar chain. Provided are: a disaccharide ...
|
|
WO/2021/043631A1 |
The present invention provides new chemical compositions, and methods for their preparation, which are industrially relevant in the manufacture of glycosaminoglycans, particularly fondaparinux.
|
|
WO/2021/037077A1 |
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2021/037205A1 |
Disclosed is a compound with a structure as shown in formula (101) and a corresponding drug conjugate, wherein the drug conjugate can be specifically targeted at cells and has a low toxicity and an excellent delivery efficiency.
|
|
WO/2021/032777A1 |
The disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The disclosure also relates to GalNAc-oligonucleotide conjugates comprising GalNAc moieties and oligonucleotides, e.g., saRNAs or siRNAs useful in regulati...
|
|
WO/2021/031594A1 |
Disclosed are a novel aromatic ring compound represented by general formula (I), an isomer, a prodrug, a solvate, a pharmaceutically acceptable salt and a pharmaceutical composition thereof, and use thereof for preparing medicaments for ...
|
|
WO/2021/034796A1 |
A process is provided for the synthesis of an intermediate of Formula 15 which is useful in the synthesis of E-selectin inhibitors. Also provided are useful intermediates obtained from the process.
|
|
WO/2021/028935A1 |
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1, R2, R3, R4, X, m and n are as defined in the specification. The present invention also relates to com...
|
|
WO/2021/023512A1 |
The invention relates to a bifunctional compound that is, on one side, an agonist of the TLR4 and, on the other side, an important inhibitor of the PSMA. Said compound is useful in immunotherapy for the treatment and/or prevention of pro...
|
|
WO/2021/020516A1 |
The present invention provides a novel steviol glycoside containing xylose. According to the present invention, there is provided a compound represented by formula (1), or a salt or hydrate thereof. (In formula, (i) R1 represents Xyl(1-2...
|
|
WO/2021/020517A1 |
The present invention provides a plant body that contains a compound represented by formula (1) [in the formula: (i) R1 represents Xyl(1-2)Glc1- and R2 represents Glc(1-2)[Glc(1-3)]Glc1-; or (ii) R1 represents Glc(1-2)[Glc(1-3)]Glc1- and...
|
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/005075A1 |
The present invention relates to the use of at least one phenolically substituted sugar derivative as a stabiliser of organic materials, in particular plastics, against oxidative, thermal and/or actinic degradation. The present invention...
|
|
WO/2020/260351A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
|
WO/2020/255989A1 |
Provided is a novel compound which is contained in a watermelon young fruit and has an antioxidative effect. A novel compound which is contained in a watermelon young fruit and is represented by formula (1) or (2) has an antioxidative ...
|
|
WO/2020/256084A1 |
A crystal of a compound represented by formula 5. In formula 5, R1 represents a hydroxyl protecting group, and R2 represents a leaving group.
|
|
WO/2020/254369A1 |
Disclosed herein are new O-biphenyl- and O-phenylheteroaryl- mannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subject...
|
|
WO/2020/252254A1 |
The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivati...
|
|
WO/2020/252294A1 |
The application relates to immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of F...
|
|
WO/2020/244253A1 |
Disclosed is an application of a small molecule compound or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor metastasis drug. The structure of the compound is as shown in formula (I). The small molecule comp...
|
|
WO/2020/247480A1 |
Described herein are composition of ascarosides, methods of using them, and the like for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of b...
|
|
WO/2020/243815A1 |
A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Com...
|
|
WO/2020/244518A1 |
The present invention provides a compound with benzyloxy aromatic ring structure represented by general formula (I), a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical c...
|
|
WO/2020/244483A1 |
Provided are novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the...
|
|
WO/2020/242796A1 |
Assays and methods for diagnosing whether a subject has a cardiovascular disease (CVD) by measuring the concentrations of nitric oxide [NO] and peroxynitrite [ONOO- ] stimulated by the different subclasses of LDL in one or more cells of ...
|
|
WO/2020/239096A1 |
A new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically discl...
|
|
WO/2020/237836A1 |
Provided is a method for preparing 4-idarubicin hydrochloride. The method comprises the step of preparing compound B into compound C in the presence of tetrabutyl ammonium halide, and the 4-idarubicin hydrochloride can be further obtaine...
|
|
WO/2020/239135A1 |
The present invention relates to a high anticoagulation activity compound, a preparation method and an application, said compound being formed from a monosaccharide unit D, a monosaccharide unit E, a 6-position carbon oxygen-substituted ...
|
|
WO/2020/234270A1 |
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10
,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car
boxylic acid with the fo...
|
|
WO/2020/236621A1 |
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administ...
|
|
WO/2020/234208A1 |
The invention comprises a process for the preparation of a GalNAc phosphoramidite epimer of the formula (I), wherein R1 is a hydroxy protecting group, n is an integer from 0 to 10 and m is an integer from 0 to 20, corresponding enantiome...
|
|
WO/2020/236684A1 |
Stevia flavor compositions comprising a high level of reb audioside AM (Reb AM) are decribed. These compositions are flavors with modifying properties, or FMPs. Using an FMP, certain flavor notes in a consumable product may be enhanced, ...
|
|
WO/2020/233680A1 |
An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a s...
|
|
WO/2020/232534A1 |
Low permeability across the outer membrane is a major reason why most antibiotics are ineffective against Gram-negative bacteria. Agents that permeabilize the outer membrane are typically toxic at their effective concentrations. Here, we...
|
|
WO/2020/231333A1 |
Provided herein are compounds, extracted from Wrightia antidysenterica, that are potent inhibitors of tyrosinase and melanogenesis, which can be used as skin whitening agents. Provided also are compositions comprising the compounds and m...
|
|
WO/2020/105054A9 |
Modified aminoglycoside compounds represented by Formula I as defined and described in the specification are provided. The modified aminoglycosides feature a diamine-containing functional moiety at one or more of positions 3', 4' and 6'....
|
|
WO/2020/218382A1 |
It has been expected to develop a novel GLP-1 secretagogue which promotes the secretion of GLP-1. The present invention provides a GLP-1 secretagogue characterized by comprising 0.4-4,440 ppm of a steviol glycoside having a structure to ...
|
|
WO/2020/219417A1 |
Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, mult...
|
|
WO/2020/219419A1 |
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by se lectin binding are described herein. For example, multimeric selectin modulators and their use are described, wherein the multimeric select...
|
|
WO/2020/213891A1 |
The present application relates to a sweetener composition comprising a fructose-transferred steviol glycoside, and a method for improving sweetness of a steviol glycoside comprising a step of converting the steviol glycoside to a fructo...
|
|
WO/2020/183442A3 |
The present disclosure relates to phenylpropanoid saccharide esters, methods for the synthesis of libraries of phenylpropanoid saccharide esters with different degree and place of substitution in the sugar core, and their use as antimicr...
|
